publication date: Feb. 26, 2016
20160226 - Feb. 26, 2016
ISSUE 8 – FEB. 26, 2016PDF

Slamming the Door

Part V: Gilman’s Resignation

Gilman’s letter of resignation, dated May 8, 2012, concludes with a hard slam:

“The purpose of this letter is to indicate my intention to resign from CPRIT, effective (with your permission) on October 12, 2012. At that time I will have worked for CPRIT for over three years—I believe longer than originally anticipated.

“During that time we have launched strong programs because funding decisions have been based on high-level competitions, where the judges have been some of the best cancer researchers and physicians in the country—free of conflicts of interest and all coming from outside of Texas.

“It was exciting to launch this program, to design effective requests for applications, and to oversee the peer review process.

Capitol Hill Briefing Focuses on Moonshot’s Provision to Integrate FDA Cancer Portfolio

When the White House proposed a $1 billion startup fund for the National Cancer Moonshot, a largely unexpected directive to reform FDA raised many questions among oncology insiders.

The agency will create a virtual Oncology Center of Excellence, the administration proposals and budget documents state.

Alas, nobody can claim to understand what “virtual” means in this context, and how the $75 million in proposed fiscal 2017 mandatory funds would be used to “leverage the combined skills of regulatory scientists and reviewers with expertise in drugs, biologics, and devices.”

In Brief

  • Laurie Glimcher named president and CEO at Dana-Farber

  • Robert Califf confirmed as FDA Commissioner

  • Mandi Pratt-Chapman named associate center director at GW Cancer Center
  • Steve Limentani named VP and chief research officer at Mission Health

  • Robert Korngold receives lifetime achievement award from the American Society for Blood and Marrow Transplantation

  • Breast Cancer Research Foundation expands research program with Pfizer portfolio

  • Bharat Aggarwal has seven papers retracted from Biochemical Pharmacology 

  • Commission on Cancer honors 27 programs for outstanding achievement

  • Kids V Cancer named one of top 10 most innovative companies

  • Indiana University Simon Cancer Center receives grant from Kay Yow Cancer Fund
Drugs and Targets

  • FDA approves Gazyva for follicular lymphoma

  • FDA approves Afinitor for GI or lung neuroendocrine tumors

  • FDA grants Breakthrough Designation to PKC412 (midostaurin)

Copyright (c) 2020 The Cancer Letter Inc.